Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-26
2005-04-26
Hartley, Michael G. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S449000, C514S492000, C514S500000, C514S510000, C514S511000, C424S649000
Reexamination Certificate
active
06884817
ABSTRACT:
Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
REFERENCES:
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5380751 (1995-01-01), Chen et al.
patent: 5422364 (1995-06-01), Nicolaou et al.
patent: 5468769 (1995-11-01), Klein et al.
patent: 5473055 (1995-12-01), Mongelli et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5489589 (1996-02-01), Wittman et al.
patent: 5569720 (1996-10-01), Mongelli et al.
patent: 5583153 (1996-12-01), Brahn
patent: 5607659 (1997-03-01), Gustavson et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5626862 (1997-05-01), Brem et al.
patent: 5641803 (1997-06-01), Carretta et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5719265 (1998-02-01), Mongelli et al.
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5783178 (1998-07-01), Kabanov et al.
patent: 5801191 (1998-09-01), Bressi et al.
patent: 5811447 (1998-09-01), Kunz et al.
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6005020 (1999-12-01), Loomis
patent: 6028164 (2000-02-01), Loomis
patent: 6156017 (2000-12-01), Shieh
patent: 6239167 (2001-05-01), Bissery
patent: 6441025 (2002-08-01), Li et al.
patent: 6515017 (2003-02-01), Li et al.
patent: 6730699 (2004-05-01), Li et al.
patent: 5286868 (1993-11-01), None
patent: WO 9310121 (1993-05-01), None
patent: WO 9503036 (1995-02-01), None
patent: WO 9513053 (1995-05-01), None
patent: WO 9625176 (1996-09-01), None
patent: WO 9733552 (1997-09-01), None
Gilbert et al., “Novel water soluble paclitaxel derivatives: Evaluation of PEG-paclitaxel's in vitro and in vivo effects,”Proc. Amer. Assoc. Cancer Res.38:225, Abstract #1512, 1997.
Pesenti et al., “Synthesis and biological activity of water soluble polymer-bound taxol derivatives,”Proc. Amer. Assoc. Cancer Res.36:307, Abstract #1824, 1994.
Vyas et al., “Phosphate-activated prodrugs of paclitaxel,” In:Taxane Anticancer Agents,George et al.; eds.,Am. Chem Soc.,Wash. D.C., Ch. 9, pp 124-137, 1995.
Yang et al., “Diagnostic and therapeutic potential of poly(benzyl L-glutamate)”J. Pharm. Sci.883:328-331, 1994.
Kuang et al., Poly(benzyl-l-glutamate microcapsules: Their diagnostic and therapeutic potential.Pharm. Res.10(10):S-191, 1993.
Li et al., “Cytotoxic and antitumor activity of water-soluble paclitaxel prodrug,” American Association Cancer Research meeting Apr. 20-Apr. 24, Abstract #2570, 1996.Proc. Am. Assoc. Cancer Res.,37:376, 1996.
Li et al., “Formation and characterization of CDDP loaded poly(benzyl l-glutamate) and poly (dl-lactic acid) microcapsules for chemoemboization,”Proc. Amer. Assoc. Cancer Res.(AACR) 35:336, 1994.
Li et al., “Synthesis and evaluation of PEG-paclitaxel conjugate as a water-soluble paclitaxel prodrug,” A.A.C.R. meeting Apr. 20-Apr. 24, Abstract #2569, 1996.Proc. Am. Assoc. Cancer Res.,37:376, 1996.
Li et al., “Water-soluble polyglutamic acid paclitaxel conjugate (PGA-paclitaxel): antitumor regression in rats braeing 13762 mammary carcinoma,” American Association Pharmaceutical Scientists meeting Oct. 27-Oct. 31, Abstract #PDD 7541, 1996.Pharmaceutical Research,13(9):S-368, 1996.
Yang et al., “Application of surface-modified microcapsules to target estrogen receptors. 7thAnnual Meeting of American Association of Pharmaceutical Scientists,” Nov. 15-1, 1992. San Antonio, Texas,Pharm. Res.9(10):S73, 1992.
Zunino et al., “Anti-tumor activity of daunorubicin linked to poly-L-aspartic acid,”Int. J. Cancer.30:465, 1982.
Pratesi et al., “Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug,”Br. J. Cancer.52:841-848, 1985.
Balog et al., “Total synthesis of (-)-epothilone A**,”Angew. Chem. Int. Ed. Engl.35:2801-2803, 1996.
Bartoni et al., “In vitro and in vivo antitumoral activity of free, and encapsulated taxol,”J. Microencapsulation,7:191-197, 1990.
Borman, S., “Epothilone epithany: total syntheses compound shares taxol's mechanism of action and is more potent in in vitro tests,”C&EN,pp. 24-26, Dec. 23, 1996.
Cortes, J.E. and Pazdur, R., “Docetaxel,”Journal of Clinical Oncology13:2643-2655, 1995.
Deutsch et al., “Synthesis of congeners and prodrugs. 3. water-soluble prodrugs of taxol with potent antitumor activity,”J. Med. Chem.,32:788-792, 1989.
Eiseman et al., “Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice,”Cancer Chemother. Pharmacol.,34:465-471, 1994.
Fidler, et al., “The biology of cancer invasion and metastasis,”Adv. Cancer Res.,28:149-250, 1978.
Goldspiel, “Pharmaceutical issues: preparation, administration, stability, and compatibility with other medications,”Ann. Pharmacotherapy,28:S23-26, 1994.
Greenwald et al., “Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness,”J. Medicinal Chemistry,39:424-431, 1996.
Greenwald et al., “Highly water soluble taxol derivatives, 7-polyethylene glycol esters as potential products,”J. Org. Chem.,60:331-336, 1995.
Greenwald et al., “Highly water soluble taxol derivative: 2′-polyethylene glycol esters as potential products,”Bioorganic&Medicinal Chemistry Letters,4:2465-2470, 1994.
Hirano et al., “Polymeric derivatives of activated cyclophosphamide as drug delivery systems in antitumor therapy pharmacologically active polymers, 20a),”Makromol. Chem.,180:1125-1130, 1979.
Hoes et al., “Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin,”J. Controlled Release,2:205-213, 1985.
Horwitz et al., “Taxol, mechanisms of action and resistance,”J. Natl. Cancer Inst. Monographs15:55-61, 1993.
Hofle, et al., “Epothilone A and B—novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution,”Angew. Chem. Int. Ed. Engl.35:1567-1569, 1996.
Kato et al., “Antitumor activity of 1-b-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative,”Cancer Res.,44:25-30, 1984.
Kopecek, “The potential of water-soluble polymeric carriers in targeted and site-specific drug delivery,”J. Controlled Release,11:279-290, 1990.
Kopecek and Kopeckova, “Targetable water-soluble-polymeric anticancer drugs: achievements and unsolved problems,”Proceed, Intern Symp. Control. Rel. Bioact. Mater.,20:190-191, 1993.
Li et al., “Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug,”Anti-Cancer Drugs,7:642-648, 1996.
Maeda and Matsumura, “Tumoritropic and lymphotropic principles of macromolecular drugs,”Critical Review in Therapeutic Drug Carrier Systems,6:193-210, 1989.
Magri and Kingston, “Modified taxols. 2. oxidation products of taxol,”J. Org. Chem.,51:797-802, 1986.
Mathew et al., “Synthesis and evalua
Li Chun
Wallace Sidney
Yang David J.
Yu Dong-Fang
Foley & Lardner LLP
Hartley Michael G.
PG-TXL Company L.P.
LandOfFree
Water soluble paclitaxel derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water soluble paclitaxel derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water soluble paclitaxel derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377722